(Q34400518)

1 August 2017

1 reference

title

Current perspectives on the role of neurosteroids in PMS and depression (English)

1 reference

1 August 2017

Griffin LD

1

1 reference

1 August 2017

Conrad SC

series ordinal

2

1 reference

1 August 2017

Mellon SH

series ordinal

3

1 reference

1 August 2017

language of work or name

1 reference

1 January 2001

1 reference

International Review of Neurobiology

1 August 2017

published in

1 reference

1 August 2017

volume

46

1 reference

1 August 2017

page(s)

479-492

1 reference

Neurosteroids: biosynthesis and function of these novel neuromodulators

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

The menstrual cycle and mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Is premenstrual dysphoric disorder a distinct clinical entity?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Biosynthesis of the neurosteroid 3 alpha-hydroxy-4-pregnen-20-one (3 alpha hp), a specific inhibitor of FSH release

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Premenstrual syndromes: closing the 20th century chapters

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Relationship between symptom severity and hormone changes in women with premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Premenstrual syndrome. Advances in diagnosis and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Serotonergic agents modulate antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Fluoxetine treatment of severe premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Allopregnanolone concentrations and premenstrual syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

The role of serotonin in premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Progesterone metabolite allopregnanolone in women with premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Effects of antidepressant treatment on neuroactive steroids in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

The neuroendocrinology of menstrual cycle mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Premenstrual syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Fluoxetine in the treatment of premenstrual dysphoria

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Synthesis, metabolism and levels of the neuroactive steroid, 3alpha-hydroxy-4-pregnen-20-one (3alphaHP), in rat pituitaries.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Selective suppression of follicle-stimulating hormone by 3 alpha-hydroxy-4-pregnen-20-one, a steroid found in Sertoli cells

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Selective suppression of follicle-stimulating hormone secretion in anterior pituitary cells by the gonadal steroid 3 alpha-hydroxy-4-pregnen-20-one

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Depression and weight gain: the serotonin connection

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Is 5HT1A receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

Female-specific mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2801%2946073-9

7 January 2021

10.1016/S0074-7742(01)46073-9

Identifiers

DOI

1 reference

1 August 2017

1 reference